Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2020

01-12-2020 | Breast Cancer | Research article

Modeling the natural history of ductal carcinoma in situ based on population data

Authors: Sarocha Chootipongchaivat, Nicolien T. van Ravesteyn, Xiaoxue Li, Hui Huang, Harald Weedon-Fekjær, Marc D. Ryser, Donald L. Weaver, Elizabeth S. Burnside, Brandy M. Heckman-Stoddard, Harry J. de Koning, Sandra J. Lee

Published in: Breast Cancer Research | Issue 1/2020

Login to get access

Abstract

Background

The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the absence of biopsy or complete excision.

Methods

Two well-established population models evaluated six possible DCIS natural history submodels. The submodels assumed 30%, 50%, or 80% of breast lesions progress from undetectable DCIS to preclinical screen-detectable DCIS; each model additionally allowed or prohibited DCIS regression. Preclinical screen-detectable DCIS could also progress to clinical DCIS or invasive breast cancer (IBC). Applying US population screening dissemination patterns, the models projected age-specific DCIS and IBC incidence that were compared to Surveillance, Epidemiology, and End Results data. Models estimated mean sojourn time (MST) in the preclinical screen-detectable DCIS state, overdiagnosis, and the risk of progression from preclinical screen-detectable DCIS.

Results

Without biopsy and surgical excision, the majority of DCIS (64–100%) in the preclinical screen-detectable state progressed to IBC in submodels assuming no DCIS regression (36–100% in submodels allowing for DCIS regression). DCIS overdiagnosis differed substantially between models and submodels, 3.1–65.8%. IBC overdiagnosis ranged 1.3–2.4%. Submodels assuming DCIS regression resulted in a higher DCIS overdiagnosis than submodels without DCIS regression. MST for progressive DCIS varied between 0.2 and 2.5 years.

Conclusions

Our findings suggest that the majority of screen-detectable but unbiopsied preclinical DCIS lesions progress to IBC and that the MST is relatively short. Nevertheless, due to the heterogeneity of DCIS, more research is needed to understand the progression of DCIS by grades and molecular subtypes.
Appendix
Available only for authorised users
Literature
1.
Oseni TO, Zhang B, Coopey SB, Gadd MA, Hughes KS, Chang DC. Twenty-five year trends in the incidence of ductal carcinoma in situ in US women. J Am Coll Surg. 2019;228(6):932–9.PubMedCrossRef
2.
Jones JL. Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective. Breast Cancer Res. 2006;8(2):204.PubMedPubMedCentralCrossRef
3.
Maxwell AJ, Clements MK, Hilton MB, Dodwell DJ, Evans A, Kearins MO, et al. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. Eur J Surg Oncol. 2018;44(4):429–35.PubMedCrossRef
4.
Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135–44.PubMedCrossRef
5.
Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Harris JR, et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin. 2002;52(5):256–76.PubMedCrossRef
6.
Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982;49(4):751–8.PubMedCrossRef
7.
Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103(12):2481–4.PubMedCrossRef
8.
Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol. 2015;28(5):662.PubMedCrossRef
9.
Rosen PP, Braun DW, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer. 1980;46(S4):919–25.PubMedCrossRef
10.
Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy. Cancer. 2005;103(9):1778–84.PubMedCrossRef
11.
Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11(3):223–35.PubMed
12.
13.
Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer. 2003;39(12):1746–54.PubMedCrossRef
14.
Seigneurin A, François O, Labarère J, Oudeville P, Monlong J, Colonna M. Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ. 2011;343:d7017.PubMedPubMedCentralCrossRef
15.
de Koning HJ, Draisma G, Fracheboud J, de Bruijn A. Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data. Breast Cancer Res. 2005;8(1):202.PubMedPubMedCentralCrossRef
16.
Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES. Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis. J Natl Cancer Inst. 2015;108(5):djv372.PubMedPubMedCentralCrossRef
17.
De Gelder R, Heijnsdijk EAM, Van Ravesteyn NT, Fracheboud J, Draisma G, De Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011;33(1):111–21.PubMedPubMedCentralCrossRef
18.
19.
Gunsoy NB, Garcia-Closas M, Moss SM. Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom. Breast Cancer Res. 2012;14(6):R152.PubMedPubMedCentralCrossRef
20.
Francis A, Fallowfield L, Rea D. The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol. 2015;27(1):6–8.CrossRef
21.
Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ–the LORD study. Eur J Cancer. 2015;51(12):1497–510.PubMedCrossRef
22.
Youngwirth LM, Boughey JC, Hwang ES. Surgery versus monitoring and endocrine therapy for low-risk DCIS: the COMET trial. Bull Am Coll Surg. 2017;102:62–3.PubMed
23.
Lee SJ, Li X, Huang H, Zelen M. The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: An Update. Med Decis Making. 2018;38(1_suppl):44S‐53S.PubMedPubMedCentralCrossRef
24.
Lee S, Zelen M. Chapter 11: a stochastic model for predicting the mortality of breast cancer. JNCI Monographs. 2006;2006(36):79–86.CrossRef
25.
van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning HJ. Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia. Med Decis Making. 2018;38(1_suppl):54S‐65S.
26.
Tan SYGL, Van Oortmarssen GJ, De Koning HJ, Boer R, Habbema JDF. Chapter 9: the MISCAN-Fadia continuous tumor growth model for breast cancer. JNCI Monographs. 2006;2006(36):56–65.CrossRef
27.
Lee SJ, Zelen M. Scheduling periodic examinations for the early detection of disease: applications to breast cancer. JASA. 1998;93(444):1271–81.CrossRef
28.
29.
Li X, Weedon-Fekjaer H, Lee SJ. Evaluating the natural history of dectal carcinomc in situ breast cancer using Norwegian breast cancer screening program data. Stat Methods Med Res. 2018:In press.
30.
van Ravesteyn NT, van den Broek JJ, Li X, Weedon-Fekjær H, Schechter CB, Alagoz O, et al. Modeling ductal carcinoma in situ (DCIS): an overview of CISNET model approaches. Med Decis Making. 2018;38(1_suppl):126S–39S.PubMedPubMedCentralCrossRef
31.
Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014;106(11):dju289.
32.
Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012. JAMA. 2018;319(2):154–64.PubMedPubMedCentralCrossRef
33.
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92.PubMedCrossRef
34.
Mandelblatt JS, Stout NK, Schechter CB, Van Den Broek JJ, Miglioretti DL, Krapcho M, et al. Collaborative modeling of the benefits and harms associated with different US breast cancer screening strategies. Ann Intern Med. 2016;164(4):215–25.PubMedPubMedCentralCrossRef
35.
Mandelblatt JS, Cronin K, de Koning H, Miglioretti DL, Schechter CS, Stout N. Modeling Report: Collaborative Modeling of U.S. Breast Cancer Screening Strategies. AHRQ Publication No. 14-05201-EF-4. Rockville, MD: U.S. Preventive Services Task Force; 2015.
36.
Ichikawa LE, Barlow WE, Anderson ML, Taplin SH, Geller BM, Brenner RJ. Time trends in radiologists’ interpretive performance at screening mammography from the community-based Breast Cancer Surveillance Consortium, 1996–2004. Radiology. 2010;256(1):74–82.PubMedPubMedCentralCrossRef
37.
Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, et al. Common model inputs used in CISNET collaborative breast cancer modeling. Med Decis Making. 2018;38(1_suppl):9S–23S.PubMedPubMedCentralCrossRef
38.
Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat. 2011;129(1):165–73.PubMedCrossRef
39.
Cronin KA, Yu B, Krapcho M, Miglioretti DL, Fay MP, Izmirlian G, et al. Modeling the dissemination of mammography in the United States. Cancer Causes Control. 2005;16(6):701–12.PubMedCrossRef
40.
Van Luijt PA, Heijnsdijk EAM, Fracheboud J, Overbeek LIH, Broeders MJM, Wesseling J, et al. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res. 2016;18(1):47.PubMedPubMedCentralCrossRef
41.
Szalayova G, Ogrodnik A, Spencer B, Wade J, Bunn J, Ambaye A, et al. Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation. Breast Cancer Res Treat. 2016;157(3):461–74.PubMedPubMedCentralCrossRef
42.
Doke K, Butler S, Mitchell MP. Current therapeutic approaches to DCIS. J Mammary Gland Biol Neoplasia. 2018;23(4):279–91.PubMedCrossRef
43.
Duffy SW, Dibden A, Michalopoulos D, Offman J, Parmar D, Jenkins J, et al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol. 2016;17(1):109–14.PubMedPubMedCentralCrossRef
44.
Seigneurin A, Labarère J, François O, Exbrayat C, Dupouy M, Filippi M, et al. Overdiagnosis and overtreatment associated with breast cancer mammography screening: a simulation study with calibration to population-based data. Breast. 2016;28:60–6.PubMedCrossRef
45.
Puliti D, Duffy SW, Miccinesi G, De Koning H, Lynge E, Zappa M, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;19(1_suppl):42–56.PubMedCrossRef
Metadata
Title
Modeling the natural history of ductal carcinoma in situ based on population data
Authors
Sarocha Chootipongchaivat
Nicolien T. van Ravesteyn
Xiaoxue Li
Hui Huang
Harald Weedon-Fekjær
Marc D. Ryser
Donald L. Weaver
Elizabeth S. Burnside
Brandy M. Heckman-Stoddard
Harry J. de Koning
Sandra J. Lee
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2020
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-020-01287-6

Other articles of this Issue 1/2020

Breast Cancer Research 1/2020 Go to the issue

Research article

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

Research article

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

Research article

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Research article

CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients

Correction

Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

Research article

ERα-36 regulates progesterone receptor activity in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits